Ovid Therapeutics (NASDAQ:OVID) Receives $6.00 Average PT from Analysts

Posted by Brian Himes on Sep 24th, 2026

Shares of Ovid Therapeutics (NASDAQ:OVID – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.00.

Several research analysts recently issued reports on the stock. B. Riley Financial reissued a “buy” rating on shares of Ovid Therapeutics in a report on Tuesday, July 21st. HC Wainwright increased their price target on Ovid Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Roth Capital reissued a “buy” rating and issued a $8.00 price objective on shares of Ovid Therapeutics in a report on Thursday, September 3rd. Oppenheimer upped their target price on Ovid Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Monday, August 3rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Ovid Therapeutics in a report on Friday, September 11th.

Get Our Latest Stock Report on Ovid Therapeutics

Ovid Therapeutics Price Performance

Shares of NASDAQ OVID opened at $2.57 on Thursday. The business’s 50 day moving average price is $2.64 and its 200 day moving average price is $2.55. The firm has a market cap of $501.92 million, a P/E ratio of -8.29 and a beta of 0.24. Ovid Therapeutics has a 52 week low of $1.18 and a 52 week high of $3.11. The company has a quick ratio of 12.39, a current ratio of 12.39 and a debt-to-equity ratio of 0.05.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.04. The company had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.02 million. Ovid Therapeutics had a negative net margin of 240.11% and a negative return on equity of 23.64%. On average, sell-side analysts expect that Ovid Therapeutics will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On Ovid Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in OVID. Legal & General Group Plc acquired a new stake in Ovid Therapeutics during the second quarter valued at $40,000. E Fund Management Co. Ltd. acquired a new position in shares of Ovid Therapeutics in the second quarter worth about $52,000. Sovereign Financial Group Inc. boosted its stake in shares of Ovid Therapeutics by 200.0% during the 1st quarter. Sovereign Financial Group Inc. now owns 30,000 shares of the company’s stock worth $67,000 after acquiring an additional 20,000 shares in the last quarter. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Ovid Therapeutics during the 2nd quarter worth about $54,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Ovid Therapeutics during the 2nd quarter valued at about $57,297. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines for rare epileptic disorders and other diseases of the brain. The company’s research programs are designed to address significant unmet needs in patients with severe neurological conditions, including developmental and epileptic encephalopathies.

Ovid has developed a pipeline of investigational therapies targeting the underlying biology of epilepsy and related neurological disorders. Its programs have included soticlestat, an investigational treatment studied in rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome, as well as earlier-stage compounds aimed at modulating neurotransmission and reducing seizure activity.

Founded in 2014 and headquartered in New York, Ovid has advanced its programs through collaborations with larger pharmaceutical companies, including a collaboration with Takeda Pharmaceutical Company involving soticlestat.